Mast Cell Tumors in Dogs: A Clear Guide for Owners, and a Note on Genetic Risk Scores

Mast cell tumors are among the more common skin cancers seen in dogs. They also tend to be highly treatable when found early, which is why awareness matters more than alarm. If your dog has received an elevated risk score on an Embark genetic panel, or if you have simply noticed a lump that gives you pause, this guide is meant to help you think clearly rather than react in fear.

Below, we walk through what mast cell tumors are, which breeds carry higher risk, how to read a genetic risk score without panic, what to watch for at home, and when to call your veterinarian. We also include guidance for fellow breeders navigating health disclosures and pairing decisions, because how a program handles this information says a great deal about its standards.

What a Mast Cell Tumor Is

Mast cells are a normal part of your dog's immune system. They live in the skin, the lining of the gut, and connective tissue, where they respond to allergens, parasites, and injury. When activated, they release histamine, heparin, and other compounds. This is the same process behind ordinary allergic reactions and inflammation.

A mast cell tumor, often shortened to MCT, forms when these cells begin multiplying abnormally and produce a mass of reactive cells. Because these cells still carry the same chemical mediators, the tumor can cause effects that reach beyond a simple skin lump.

Why MCTs Are Sometimes Called "The Great Pretender"

Mast cell tumors can resemble almost anything. They may feel like a soft, fatty lump. They may look like a raised, hairless bump. They may appear as an inflamed red patch that mimics an insect bite. This variability is precisely why a visual check alone is not enough, and why a cytology test is generally considered essential for a clear answer.

Physical handling of a suspected MCT can make matters worse. Squeezing or pressing on one can trigger the cells to release their contents, which sometimes causes sudden swelling, bruising, and redness at the site. In more serious cases, it can contribute to gastrointestinal upset or a systemic reaction. The guidance is simple. If you find a lump, leave it alone and call your veterinarian.

How Mast Cell Tumors Are Graded, and Why It Matters

Not every mast cell tumor behaves the same way. Veterinary pathologists use grading systems to sort them, from slow growing and indolent to fast moving and aggressive. Understanding this helps owners and veterinarians make informed decisions together.

The Two Main Grading Systems

The Patnaik system uses three grades. Grade I tumors are well differentiated, generally confined to the skin, and tend to carry a favorable outlook, with research reporting that a large majority of dogs survive well past four years following surgery. Grade II tumors are intermediate and less predictable, and studies suggest roughly half of affected dogs survive past four years with surgery. Grade III tumors are poorly differentiated and behave more aggressively, and the reported outlook is considerably less favorable without systemic treatment.

The Kiupel system simplifies grading into two tiers, low grade and high grade, using more objective cellular criteria. Under this system, high grade tumors are generally associated with a much shorter median survival without treatment, while low grade tumors tend to carry a more favorable long term outlook.

What Happens After Grading

When a grade falls in a borderline range, pathologists can run additional tests, including mitotic count, the Ki67 index, and KIT receptor staining. These markers help identify tumors that look intermediate on the surface but may carry higher risk features underneath. The goal is a clearer picture, not a faster one.

Breed, Ancestry, and Genetic Risk

Some breeds are meaningfully more likely to develop mast cell tumors than others. This is not random. Over generations, selective breeding has concentrated certain genetic risk factors in specific lineages.

Breeds Often Associated With Higher Risk

Boxers are frequently cited as carrying substantially elevated MCT risk relative to mixed breed dogs, though they tend to develop lower or intermediate grade tumors with a more favorable outlook, often diagnosed around seven years of age. Pugs frequently develop multiple tumors at once, though these are usually low grade and clinically quiet. French Bulldogs show a notable association with tumors on the trunk, generally low to intermediate grade, with peak risk reported between roughly seven and ten years.

Golden Retrievers are prone to developing more than one primary tumor over a lifetime. Most are low grade, although higher grade cases have been documented. Labrador Retrievers carry moderate risk, particularly on the limbs and trunk, and early spay or neuter appears to raise that risk further, a point we return to below. Chinese Shar-Peis are a notable concern, as they more often develop poorly differentiated, high grade tumors at a younger age, which makes close monitoring especially important in that breed.

Breeds Often Associated With Lower Risk

German Shepherd Dogs and Cocker Spaniels both tend to show reduced MCT risk compared with mixed breeds. Worth noting, when German Shepherds do develop MCTs, a higher proportion are reported to be high grade, so vigilance still has value even in lower risk breeds.

What the Genetics Suggest

Genome wide studies in Golden Retrievers have identified several germline risk factors. A variant in the GNAI2 gene appears to disrupt normal signaling in mast cells. Separate risk haplotypes, which differ between European and US Golden Retriever populations, affect gene clusters that regulate how the surrounding tissue matrix breaks down. Abnormal tissue remodeling at this level is thought to create conditions that favor tumor development.

Acquired mutations also play a role. Research indicates that a meaningful share of skin MCTs carry mutations in the c-KIT gene, in a region known as exon 11. These mutations can cause the KIT receptor to remain switched on, which drives continued cell growth. They are often associated with higher grade behavior and can help guide treatment, particularly for targeted therapies such as toceranib and masitinib.

Reading Embark's MCT Risk Score Without Panic

Embark's mast cell tumor assessment is a polygenic risk score. It is not a diagnostic test, and it is not a prediction of certainty. It combines breed ancestry, hundreds of genetic markers across the genome, biological sex, and owner reported health information to estimate relative lifetime risk.

Absolute Risk Versus Relative Risk

This distinction matters a great deal for how you respond to a result.

Consider an example. Suppose Embark reports that 88 out of every 1,000 dogs with your dog's genetic profile develop MCTs in their lifetime, compared with 37 out of 1,000 in the general population. Your dog's absolute genetic risk is about 8.8 percent. The population average is about 3.7 percent. The relative risk is roughly 2.4 times higher.

The relative figure can sound alarming. The absolute figure tells a calmer story. In that example, there is still better than a 91 percent likelihood your dog never develops a mast cell tumor. Even at lower scores, a dog showing an elevated relative risk often still has a very high chance of remaining tumor free across its life. The value of the score lies in prompting earlier, more systematic monitoring, which is genuinely worthwhile. It is a signal to be watchful, not a verdict.

Who Can and Cannot Receive a Score

Embark's model was built and validated primarily for bulldog, bully, and retriever type ancestries. Dogs of other lower risk backgrounds tested before March 2026 may not receive an MCT result. Dogs that cannot be genetically identified as male or female are also excluded, because sex is one of the model's inputs. Large scale data suggests females show a slightly higher MCT rate.

What to Watch For at Home

Early detection tends to improve outcomes considerably. A large majority of skin MCTs are low to intermediate grade and can often be fully addressed with surgery when caught early. A simple home routine makes a real difference.

Monthly Skin Checks

Once a month, run flat hands across your dog's entire body, including the head, neck, trunk, limbs, and tail. You are feeling for any new raised area, any lump beneath the skin, or any change to a lump you already know about. Note size, texture, and whether it moves freely.

Pay particular attention to the mouth and lip folds, the areas where skin meets mucous membrane, and the lower limbs and toes, since tumors in those locations are reported to trend toward higher grades.

Signs That Warrant Prompt Veterinary Attention

• A lump that seems to swell and shrink over a day or two. This fluctuation is a recognized sign caused by the cells releasing their contents.

• Any new skin mass, regardless of how harmless it appears.

• Ongoing vomiting, dark or tarry stools, poor appetite, or unexplained abdominal discomfort, which can indicate that histamine from a tumor is irritating the gut.

• Sudden redness, swelling, or bruising around a known lump after it has been touched or irritated.

What to Expect at the Veterinarian

If a suspicious mass is found, your veterinarian will often recommend a fine needle aspirate, a quick and minimally invasive step that draws cells for evaluation under a microscope. Mast cell tumors tend to shed cells readily and are usually identifiable by their distinctive granular appearance. This step is generally considered safe, fast, and highly informative, and it is widely regarded as the appropriate first move.

If cytology confirms an MCT, your veterinarian may recommend further grading through histopathology, assessment of nearby lymph nodes, and in some cases imaging of the liver and spleen for staging, particularly with higher grade or rapidly growing masses.

Treatment Options in Brief

Treatment decisions depend on grade, location, staging, and whether the tumor carries actionable mutations. The following is general information, not medical advice, and your veterinarian is the right person to guide any specific case.

Surgical removal remains the primary approach for most localized MCTs. Wide margins are typically recommended, and research reports high rates of complete removal in low grade cases when those margins are achieved. Radiation therapy is often used as a follow up option when surgical margins are incomplete, and is reported to reduce the chance of local recurrence. Targeted therapies, such as toceranib and masitinib, can be effective for tumors carrying c-KIT exon 11 mutations, for masses that cannot be removed surgically, or where spread has been confirmed. An injectable option known as tigilanol tiglate is approved for certain localized, non spreading skin MCTs, and clinical trials have reported favorable response rates, with treatment generally requiring supportive medication and a wound that heals over several weeks.

Guidance for Breeders

If you steward a predisposed line and a dog in your program receives an elevated Embark MCT risk score, here is what a responsible response generally looks like. At Stokeshire, this is the same standard we hold ourselves to. You can read more about how we back that commitment in our health guarantee.

Do Not Over-React to a Risk Score

MCT risk is polygenic. Hundreds of small effect variants interact with sex, age, and environment, and there is no single gene to test for and remove. Eliminating every dog with an elevated score from a program would narrow genetic diversity, which can worsen other concerns over time, including joint disease, cardiac conditions, and other cancers. A risk score is one data point among many.

The sound approach is to pair a dog carrying an elevated score with a partner carrying an average or below average score, and to weigh that alongside temperament, structure, longevity records, and the overall diversity of the program. This is the quiet discipline behind responsible breeding. It rarely makes for a dramatic story, and that is exactly the point. If you'd like to see how this plays out in practice, you're welcome to meet our breeding dogs.

Communicating With Families

Transparency builds trust, and context prevents unnecessary worry. When sharing an elevated MCT risk score with a family, we frame it plainly. We explain that the score reflects elevated relative risk, not a diagnosis or a certainty. We walk through the absolute numbers, which generally show that most dogs with the profile never develop an MCT. We provide a clear plan, including monthly skin checks and prompt evaluation of any lump. And we position the result as a tool for proactive care rather than a reason for alarm.

A Note on Spay and Neuter Timing

The timing of spay or neuter can influence MCT risk in predisposed dogs. In Golden Retrievers, research has reported a measurable rise in MCT incidence in spayed females compared with intact females, with the reported rate differing by whether the procedure occurred before or after twelve months. In Vizslas, studies have reported a notable increase in MCT risk in altered dogs of both sexes.

This does not argue against spay or neuter. It argues for breed specific, well timed decisions made in consultation with your veterinarian, rather than a single policy applied to every dog. For breeds with meaningful MCT predisposition, preserving reproductive hormones through at least twelve to eighteen months of age is often worth discussing.

Putting It Together

An elevated genetic risk score, or even a diagnosis, does not have to become a source of fear. The pattern in the research is consistent. Early detection, steady monitoring, and prompt evaluation tend to give most dogs a strong chance at a full recovery.

A simple place to begin:

• Start monthly skin checks using the flat hand technique, and note any lump you find.

• Never squeeze a suspicious lump. Contact your veterinarian instead.

• Ask for a fine needle aspirate on any new or changing mass, without long delay.

• Discuss spay and neuter timing with your veterinarian in the context of your dog's breed and individual profile.

• Treat an Embark risk score as a planning tool rather than a verdict. It tells you to stay watchful, not to worry.

The strongest outcomes tend to come from owners who know what to look for and veterinarians who have the information they need to act. That partnership is what turns a manageable condition into a manageable life, and it is the same principle of informed, unhurried care that guides everything we do at Stokeshire.